• Click here to download the course flyer with the detailed educational program (updates with faculty names available; send your request to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it )
• If you are interested in participating in the 2010 training course, please click here to access the course registration website to secure your place in the upcoming course and to reserve hotel accommodation at a reduced rate at the course venue.  

Educational aims
The process of developing new anticancer agents is distinctly different from drug development in many other therapeutic areas. This intensive training course is primarily designed to provide specific knowledge on the preclinical and clinical development of new agents intended for the treatment of cancer in particular in Europe. The course will also address strategic, regulatory and scientific issues in the development of such agents. Since successful anticancer drug development requires basic understanding of tumor (molecular) biology and cancer patient management, an important part of the educational program is devoted to tumor biology, pathology and clinical management of patients with cancer. The latter will be illustrated by expert reviews of breast cancer, lung cancer, and hematological malignancies.

Educational themes
• Cancer definitions and frequently used terminology, epidemiology
• Carcinogenesis & tumor biology
• Oncopathology
• Treatment modalities in cancer
• Current treatment strategies in breast cancer, lung cancer, hemato-oncology
• Medical image management and tumor response evaluation
• Preclinical drug development
• Early phase clinical studies
• Full clinical development
• Post-registration studies
• Clinical trial design in oncology
• Regulatory issues in anticancer drug development

Course format
The course will be an intensive educational event with sessions of 1 to 1.5 hours duration each. Each session will address a specific topic and will be presented by expert faculty from academia or industry. There will be ample opportunity for interaction with the faculty both during the sessions as well as during the breaks and meals. The program will include group tasks in small groups. A maximum of 30 participants will be accepted to secure the optimal educational setting.
All educational materials and presentations will be provided in print in the course binder (at the start of the course) and in digital format (at the end of the course).

Faculty
Experts in the relevant disciplines of oncology and anticancer drug research and development have been recruited to the course faculty. Faculty members will be renowned experts from leading academic research institutes and oncology-orientated drug companies. This ensures that the education provided will be highly up-to-date and based upon experience gained in actual drug development practice.

Who should participate?
The course is intended for everyone who wishes to acquire (or improve) knowledge of the development of new anticancer agents. The course is primarily intended for professionals involved in anticancer drug development in industry and the CRO environment, but professionals from other types of organizations are equally welcome. An understanding of the basic principles of biology and medicine at graduate level is required for successful participation in the course.

Course management and information
MCCM Meeting Management BV
P.O. Box 77
3480 DB Harmelen
The Netherlands 
Tel: +31 (0)88-089 8100
Fax: +31 (0)88-089 8109
Email: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it